drugset / Trial / NCT02340962
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination with Peg-interferon and Ribavirin in Treatment Naïve East Asian Subjects with Chronic Hepatitis C Virus Genotype 1b Infection.
Timeline
- Start
- 2015-05
- Primary completion
- 2016-08-12
- Completion
- 2016-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furaprevir | Small molecule | 200 mg | Oral |
| Subject | Furaprevir | Small molecule | 400 mg | Oral |
| Background | Ribavirin | Small molecule | — | Oral |
| Background | interferon alfa | Protein / enzyme biologic | 180 ug | Subcutaneous |